Reuters
2022.06.22 05:02

Precision Biosciences Announces In Vivo Gene Editing Collaboration With Novartis

June 21 (Reuters) - Precision BioSciences Inc:

June 21 (Reuters) - Precision BioSciences Inc (DTIL.O) :

  • PRECISION BIOSCIENCES ANNOUNCES IN VIVO GENE EDITING COLLABORATION WITH NOVARTIS TO DEVELOP POTENTIALLY CURATIVE TREATMENT FOR DISORDERS INCLUDING SICKLE CELL DISEASE

  • PRECISION BIOSCIENCES INC - PRECISION TO RECEIVE $75 MILLION UPFRONT FOR A SINGLE TARGET

  • PRECISION BIOSCIENCES - PRECISION ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $1.4 BILLION IN MILESTONES AND TIERED ROYALTIES ON SALES OF LICENSED PRODUCTS

  • PRECISION BIOSCIENCES INC - EXTENDS PRECISION’S CASH RUNWAY INTO Q2 2024

The copyright of this article belongs to the original author/organization.
The current content only represents the author’s point of view, and has nothing to do with the position of Longbridge. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by Longbridge, please contact: editorial@longbridge.global

Like